The National Medical Products Administration recently issued a notice that after inspection by 7 drug inspection institutions including Guangdong Provincial Institute of Drug Control, 28 batches of drugs produced by 24 enterprises did not meet the regulations. After inspection by the Guangdong Provincial Drug Inspection Institute, a total of four batches of Coenzyme Q10 Injection produced by Liaoning Zhonghai Kang Biopharmaceutical Co., Ltd., Jiangsu Wanbang Biochemical Pharmaceutical Group Co., Ltd., and Kangpu Pharmaceutical Co., Ltd. did not meet the regulations. The non compliant items included characteristics, insoluble particles, visible foreign substances, and content determination. After inspection by Anhui Food and Drug Inspection and Research Institute, it was found that two batches of sodium bicarbonate injection produced by Chenxin Pharmaceutical Co., Ltd. and China Resources Shuanghe Limin Pharmaceutical (Jinan) Co., Ltd. did not meet the regulations. The non compliant items involved visible foreign objects and pH values. After inspection by the Xizang Autonomous Region Institute for Food and Drug Control, 808 scarlet was detected in two batches of 25 flavor coral pills produced by Xizang Changdu Guangyulimin Pharmaceutical Co., Ltd., and the inspection item was 808 scarlet. After inspection by Hubei Provincial Institute of Drug Supervision and Inspection, it was found that the first batch of mulberry bark produced by Chengdu Tiansheng Traditional Chinese Medicine Pieces Co., Ltd. did not meet the requirements, and the non compliant item was the appearance. After inspection by the China National Institute for Food and Drug Control, a total of 7 batches of Pueraria lobata produced by Zhejiang Dadetang National Pharmaceutical Co., Ltd., Hunan Taoyuan Traditional Chinese Medicine Decoction Pieces Co., Ltd., Sichuan Jinke Pharmaceutical Co., Ltd., Sichuan Shengshi Jinrong Pharmaceutical Co., Ltd., and Sichuan Yifang Traditional Chinese Medicine Decoction Pieces Co., Ltd. do not meet the regulations. The non compliant item is the appearance. After inspection by Hunan Provincial Institute of Drug Inspection and Testing, a total of 7 batches of red ginseng (red ginseng tablets) produced by Hebei Runhua Pharmaceutical Co., Ltd., Hebei Yida Pharmaceutical Co., Ltd., Jilin Aodong Shihang Pharmaceutical Co., Ltd., Anhui Baicui Jinfang Pharmaceutical Co., Ltd., Dade Kangyuan (Fujian) Pharmaceutical Co., Ltd., Linyi Baiguo Traditional Chinese Medicine Pieces Co., Ltd., and Guizhou Jintianli Pharmaceutical Co., Ltd. were found to be non compliant with regulations. The non compliant items involve residual amounts, identification, and properties of other organochlorine pesticides. After inspection by Shenzhen Institute of Drug Control, a total of 5 batches of wild chrysanthemums produced by Anhui Huatianbao Traditional Chinese Medicine Decoction Pieces Co., Ltd., Anhui Xusong Traditional Chinese Medicine Decoction Pieces Co., Ltd., Sichuan Hemuyuan Pharmaceutical Co., Ltd., Guiyang Daosheng Health Industry Co., Ltd., and Guizhou Shanhaitongjia Pharmaceutical Co., Ltd. did not meet the regulations. The non compliant item is content determination. The National Medical Products Administration stated that for the above-mentioned drugs that do not comply with regulations, the drug supervision and management department has required relevant enterprises and units to take risk control measures such as suspending sales and use, recalling, and conducting investigations into the reasons for non-compliance and effectively rectifying them. The National Medical Products Administration requires relevant provincial drug supervision and management departments to organize investigations into suspected illegal activities of the above-mentioned enterprises and units in accordance with the Drug Administration Law of the People's Republic of China, and publicly disclose the results of the investigation in accordance with regulations. (New Society)